Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- iHealthScreen Inc. Announces UK Medicines and Healthcare Products Regulatory Agency (MHRA) Certification and registration for iPredict™ - Automated AI System for Early ...
Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular degeneration (AMD), and Glaucoma, and help prevent blindness ...
- EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
EyePoint Pharmaceuticals, Inc. EYPT, a clinical-stage company, announced positive top-line results from a mid-stage study of its investigational candidate, EYP-1901, in the treatment of wet ...
- Diabetic Macular Edema drugs in development, 2023
The Diabetic Macular Edema drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by ...
- EyePoint Pharmaceuticals’ stock soars 200% after company announces positive data for macular degeneration treatment
EyePoint Pharmaceuticals Inc.’s stock rocketed 200% on Monday, after the company announced positive results from a Phase 2 trial of its EYP-1901 treatment for wet age-related macular degeneration, or ...
- Watertown biotech shares surge nearly 200% on new drug data
Shares of a Watertown biotech were up nearly 200% in morning trading on Monday, following good news about an eye disease drug.
Go deeper with Google Headlines on:
Diabetic macular edema
[google_news title=”” keyword=”diabetic macular edema” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Diabetes related vision loss
- What to Know About Diabetic Retinopathy
While treatment may be able to prevent damage to the retina before this occurs, once it happens, it cannot be undone, and any related vision loss is permanent. If you have any form of diabetes, you ...
- Stiffening of retinal blood vessels threatens vision in diabetes
Using atomic force microscopy, researchers at Doheny Eye Institute, an affiliate of UCLA, discovered retinal capillary stiffening in diabetic mice that is causally linked to the development of ...
- Preventing vision loss from diabetes
The prevalence of diabetic retinopathy in Malaysia has been reported to range from 44.1% to 48.6%; while other studies show 12.3% for Type 1 diabetes mellitus and 22.3% for Type 2 diabetes mellitus.
- Mary Tyler Moore’s Jewelry Collection Going to Auction, Raising Funds to Combat Diabetes-Related Vision Loss
Necklaces, rings and timepieces owned by the beloved star will be sold at Sotheby's in December with proceeds benefiting the Mary Tyler Moore Vision ... visual loss and blindness from diabetes.
- Diabetes Awareness Month highlights importance of eye care for vision loss prevention: Canadian Ophthalmological Society
Book a comprehensive eye exam every year, as early detection is the best way to prevent vision loss. Follow the specified diabetes regime set by your healthcare team, and discuss the barriers that ...
Go deeper with Google Headlines on:
Diabetes related vision loss
[google_news title=”” keyword=”diabetes related vision loss” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]